



MY2025 MEDICAID HEDIS® REFERENCE SHEET FOR PROVIDERS

ADULT HEDIS® MEASURES

HEDIS MEASURE	AGE	MEASURE DESCRIPTION	BILLING CODES
Adults' Access to Preventive/Ambulatory Health Services (AAP)	20 years of age and older	The percentage of members, 20 years of age and older, who had an ambulatory or preventive care visit during the measurement year.	CPT: 92002, 92004, 92012, 92014, 98966-98968, 98970-98972, 98980, 98981, 99202-99205, 99211-99215, 99242-99245, 99304-99310, 99315, 99316, 99341-99342, 99344-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99421-99423, 99429, 99441-99443, 99457, 99458, 99483 HCPCS: G0071, G0402, G0438, G0439, G0463, G2010, G2012, G2250-G2252, S0620, S0621, T1015 UBREV: 0510-0517, 0519-0529, 0982, 0983 ICD-10: Z00.00, Z00.01, Z00.121, Z00.129, Z00.3, Z00.5, Z00.8, Z02.0-Z02.6, Z02.71, Z02.79, Z02.81-Z02.83, Z02.89, Z02.9, Z76.1, Z76.2 Note: Do not include laboratory claims (POS 81).
Timeliness of Prenatal Care (PPC)	All Pregnant Women	The percentage of deliveries of live births on or between October 8 th of the year prior to the measurement year and October 7 th of the measurement year that received a prenatal care visit in the first trimester, on or before the enrollment start date or within 42 days of enrollment in the health plan, with an OB/GYN, other prenatal care practitioner or PCP. For visits to a PCP, a diagnosis of pregnancy must be present.	Prenatal Care Visits CPT: 98966-98968, 98970-98972, 98980, 98981, 99202-99205, 99211-99215, 99241-99245, 99421-99423, 99441-99443, 99457, 99458, 99483 HCPCS: G0071, G0463, G2010, G2012, G2250-G2252, T1015 Stand Alone Prenatal Visits CPT: 99500 CPT II: 0500F, 0501F, 0502F HCPCS: H1000-H1004 Note: Do not include codes with a CPG CAT II Modifier (1P-3P, 8P) Prenatal Bundled Services CPT: 59400, 59425, 59426, 59510, 59610, 59618 HCPCS: H1005 Note: Because bundled service codes are used on the date of delivery, these codes may be used only if the claim form indicates when prenatal care was initiated; <i>claim form must include prenatal visit Date of Service (DOS).</i> Pregnancy Diagnosis ICD-10: O09.00-O16.09, O20.0-O26.93, O28.0-O36.93X9, O40.1XX0-O48.1, O60.00, O60.03, O71.00-O71.9, O88.011-O88.819, O91.011-O92.79, O98.011-O99.891, O9A.111-O9A.519, Z03.71-Z03.75, Z03.79, Z32.01, Z34.00-Z34.93, Z36.0-Z36.9
Postpartum Care (PPC)	All women who delivered a baby	The percentage of deliveries of live birth on or between October 8 th of the year prior to the measurement year and October 7 th of the measurement year that had a postpartum visit with an OB/GYN practitioner or other prenatal care practitioner, or PCP on or between 7 and 84 days after delivery. Any of the following meet criteria: <ul style="list-style-type: none"> • A postpartum visit. • An encounter for postpartum care. • Cervical cytology. • A bundled service where the organization can identify the date when postpartum care was rendered. 	Postpartum Care CPT: 57170, 58300, 59430, 99501 CPT II: 0503F HCPCS: G0101 Note: Do not include codes with a CPT CAT II Modifier (1P-3P, 8P) Encounter for Postpartum Care ICD-10: Z01.411, Z01.419, Z01.42, Z30.430, Z39.1, Z39.2 Note: Do not include laboratory claims (claims with POS code 81). Cervical Cytology CPT: 88141-88143, 88147, 88148, 88150, 88152, 88153, 88164-88167, 88174, 88175 HCPCS: G0123, G0124, G0141, G0143-G0145, G0147, G0148, P3000, P3001, Q0091 Postpartum Bundled Services CPT: 59400, 59410, 59510, 59515, 59610, 59614, 59618, 59622 Note: Because bundled service codes are used on the date of delivery and not on the date of the postpartum visit, these codes may be used only if the claim form indicates when postpartum care was rendered; <i>claim form must include postpartum visit Date of Service (DOS).</i>



MY2025 MEDICAID HEDIS[®] REFERENCE SHEET FOR PROVIDERS

Statin Therapy for Patients with Diabetes (SPD)	40-75 years (diabetics)	<p>The percentage of members 40 – 75 years of age during the measurement year with diabetes who do not have clinical atherosclerotic cardiovascular disease (ASCVD) who met the following criteria. Two rates are reported:</p> <ul style="list-style-type: none"> Received Statin Therapy. Members who were dispensed at least one statin medication of any intensity during the measurement year. Statin Adherence 80%. Members who remained on a statin medication of any intensity for at least 80% of the treatment period. 	<p>High-Intensity Statin Therapy Amlodipine-atorvastatin 40-80 mg, Atorvastatin 40-80 mg, Ezetimibe-simvastatin 80 mg, Rosuvastatin 20-40 mg, Simvastatin 80 mg</p> <p>Moderate-Intensity Statin Therapy Amlodipine-atorvastatin 10-20 mg, Atorvastatin 10-20 mg, Ezetimibe-simvastatin 20-40 mg, Fluvastatin 40-80 mg, Lovastatin 40 mg, Pitavastatin 1-4 mg, Pravastatin 40-80 mg, Rosuvastatin 5-10 mg, Simvastatin 20-40 mg</p> <p>Low-Intensity Statin Therapy Ezetimibe-simvastatin 10 mg, Fluvastatin 20 mg, Lovastatin 10-20 mg, Pravastatin 10-20 mg, Simvastatin 5-10 mg</p>
Blood Pressure Control for Patients with Diabetes (BPD)	18-75 years (diabetics)	<p>The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose blood pressure (BP) was adequately controlled (<140/90 mm Hg) during the measurement year.</p>	<p>Systolic Blood Pressure CPT II: 3074F (if Systolic <130 mm Hg) = COMPLIANT CPT II: 3075F (if Systolic 130-139 mm Hg) = COMPLIANT CPT II: 3077F (if Systolic ≥ 140 mm Hg) = NOT COMPLIANT</p> <p>Diastolic Blood Pressure CPT II: 3078F (if Diastolic <80 mm Hg) = COMPLIANT CPT II: 3079F (if Diastolic 80-89 mm Hg) = COMPLIANT CPT II: 3080F (if Diastolic ≥ 90 mm Hg) = NOT COMPLIANT</p>
Eye Exam for Patients with Diabetes (EED)	18-75 years (diabetics)	<p>The percentage of members 18–75 years of age with diabetes (types 1 and 2) who had an eye exam (retinal) performed during the measurement year.</p>	<p>Retinal Eye Exams CPT: 92002, 92004, 92012, 92014, 92018, 92019, 92134, 92201, 92202, 92230, 92235, 92250, 99203-99205, 99213-99215, 99242-99245</p> <p>HCPCS: S0620, S0621, S3000</p> <p>Retinal Imaging CPT: 92227, 92228</p> <p>Codes to Identify Eye Exam (with an Eye Care Professional billed by any Provider) CPT: 92229 CPT II: 2022F-2026F, 2033F</p>
Glycemic Status Assessment for Patients with Diabetes (GSD)	18-75 years (diabetics)	<p>The percentage of members 18–75 years of age with diabetes (types 1 and 2) whose most recent glycemic status (hemoglobin A1c [HbA1c] or glucose management indicator [GMI]) was at the following levels during the measurement year:</p> <ul style="list-style-type: none"> Glycemic Status <8.0%. Glycemic Status >9.0%. 	<p>HbA1c Lab Test CPT: 83036, 83037 LOINC: 97506-0</p> <p>HbA1c Test Result or Findings CPT II: 3044F – Results HbA1c < 7.0 CPT II: 3046F – Results HbA1c > 9% CPT II: 3051F – Results HbA1c ≥ 7.0% to < 8.0% CPT II: 3052F – Results HbA1c > 8.0% to ≤ 9.0%</p>
Kidney Health Evaluation for Patients with Diabetes (KED)	18-85 years	<p>The percentage of members 18-85 years of age with diabetes (type 1 and type 2) who received kidney health evaluation, defined by an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR), during the measurement year.</p>	<p>Estimated Glomerular Filtration Rate Lab Test: CPT: 80047, 80048, 80050, 80053, 80069, 82565</p> <p>Quantitative Urine Albumin Lab Test: CPT: 82043</p> <p>Urine Creatinine Lab Test: CPT: 82570</p>
Colorectal Cancer Screening (COL-E)	45-75 years old	<p>The percentage of members 45-75 years of age who had one of the following screenings for colorectal cancer:</p>	<p>sDNA FIT Lab Test CPT: 81528</p> <p>FOBT Lab Test CPT: 82270, 82274</p> <p>HCPCS: G0328</p> <p>Flexible Sigmoidoscopy CPT: 45330-45335, 45337, 45338, 45340-45342, 45346, 45347, 45349, 45350</p> <p>HCPCS: G0104</p> <p>Colonoscopy CPT: 44388-44394, 44401-44408, 45378-45393, 45398</p> <p>HCPCS: G0105, G0121</p> <p>CT Colonography CPT: 74261-74263</p>
Appropriate use of imaging studies for low back pain (LBP)	18-85 years old	<p>The percentage of members 18–75 years of age with a principal diagnosis of low back pain who did not have an imaging study (plain X-ray, MRI, CT scan) within 28 days of the diagnosis.</p>	<p>Imaging Study CPT: 72020, 72040, 72050, 72052, 72070, 72072, 72074, 72080-72084, 72100, 72110, 72110, 72114, 72120, 72125-72133, 72141, 72142, 72146-72149, 72156-72158, 72200, 72202, 72220</p>



MY2025 MEDICAID HEDIS[®] REFERENCE SHEET FOR PROVIDERS

Plan all-cause readmissions (PCR)	18 years and older	Members 18 years of age and older, the number of acute inpatient and observation stays during the measurement year that were followed by an unplanned acute readmission for any diagnosis within 30 days and the predicted probability of an acute readmission.	<p>Inpatient Stay UBREV: 0100, 0101, 0110-0114, 0116-0124, 0126-0134, 0136-0144, 0146-0154, 0156-0160, 0164, 0167, 0169-0174, 0179, 0190-0194, 0199-0204, 0206-0214, 0219, 1000-1002</p> <p>Observation Stay UBREV: 0760, 0762, 0769</p>
Prenatal Immunization Status (PREE)	All pregnant women	The percentage of deliveries in the measurement period (January 1 - December 31) in which members had received influenza and tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccinations.	<p>Adult Influenza Vaccine Procedure CPT: 90630, 90653, 90654, 90656, 90658, 90661, 90662, 90673, 90674, 90682, 90686, 90688, 90689, 90694, 90756</p> <p>Tdap Vaccine Procedure CPT: 90715</p>
Statin Therapy for Patients with Cardiovascular Disease (SPC)	21-75 years	<p>The percentage of males 21-75 years of age and females 40-75 years of age during the measurement year, who were identified as having clinical atherosclerotic cardiovascular disease (ASCVD) and met the following criteria. Two rates are reported:</p> <ul style="list-style-type: none"> • <i>Received Statin Therapy.</i> Members who were dispensed at least one high-intensity or moderate-intensity statin medication during the measurement year. • <i>Statin Adherence 80%.</i> Members who remained on a high-intensity or moderate-intensity statin medication for at least 80% of the treatment period. 	<p>High-intensity Statin Therapy Atorvastatin 40–80 mg, Amlodipine-atorvastatin 40-80 mg, Ezetimibe-simvastatin 80 mg, Rosuvastatin 20–40 mg, Simvastatin 80 mg</p> <p>Moderate-intensity Statin Therapy Atorvastatin 10–20 mg, Amlodipine-atorvastatin 10-20 mg, Ezetimibe-simvastatin 20-40 mg, Rosuvastatin 5–10 mg, Simvastatin 20–40 mg, Fluvastatin 40–80 mg, Pravastatin 40–80 mg, Lovastatin 40 mg, Pitavastatin 1–4 mg,</p>
Risk of Continued Opioid Use (COU)	18 years and older	<p>The percentage of patients 18 years of age and older who have a new episode of opioid use that puts them at risk for continued opioid use. Two rates are reported:</p> <ul style="list-style-type: none"> • The percentage of patients with at least 15 days of prescription opioids in a 30-day period. • The percentage of patients with at least 31 days of prescription opioids in a 62-day period. 	<p>Opioid Medications Benzhydrocodone, Buprenorphine (transdermal patch and buccal film), Butorphanol, Codeine, Dihydrocodeine, Fentanyl, Hydrocodone, Hydromorphone, Levorphanol, Meperidine, Methadone, Morphine, Opium, Oxycodone, Oxymorphone, Pentazocine, Tapentadol, Tramadol</p>
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD)	18-64 years	The percentage of members 18-64 years of age with schizophrenia, schizoaffective disorder, or bipolar disorder, who were dispensed an antipsychotic medication and had a diabetes screening test (glucose test or HbA1c test) during the measurement year.	<p>Medication List: Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Haloperidol, Iloperidone, Loxapine, Lumateperone, Lurasidone, Molindone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone, Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Haloperidol, Iloperidone, Loxapine, Lumateperone, Lurasidone, Molindone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone, Amitriptyline-perphenazine, Thiothixen, Aripiprazole, Aripiprazole lauroxil, Fluphenazine decanoate, Haloperidol decanoate, Olanzapine, Paliperidone palmitate, Risperidone</p>
Use of Opioids at High Dosage (HDO)	18 years and older	The percentage of members 18 years of age or older who received prescription opioids at a high dosage (average morphine milligrams equivalent dose [MME] ≥90) for ≥15 days during the measurement year.	<p>Medication List Benzhydrocodone, Butorphanol, Codeine, Dihydrocodeine, Fentanyl, Hydrocodone, Hydromorphone, Levorphanol, Meperidine, Methadone, Morphine, Opium, Oxycodone, Oxymorphone, Pentazocine, Tapentadol, Tramadol</p>

Use of Opioids from Multiple Providers (UOP)	18 years and older	<p>The proportion of patients 18 years of age and older, receiving prescription opioids for greater than or equal to 15 days during the measurement year, who received opioids from multiple providers. Three rates are reported:</p> <ul style="list-style-type: none"> • Multiple Prescribers. The proportion of patients receiving prescriptions for opioids from 4 or more different prescribers during the measurement year. • Multiple Pharmacies. The proportion of patients receiving prescriptions for opioids from 4 or more different pharmacies during the measurement year. • Multiple Prescribers and Multiple Pharmacies. The proportion of patients receiving prescriptions for opioids from four or more different prescribers and four or more different pharmacies during the measurement year. 	<p>Medication List Benzhydrocodone, Buprenorphine (transdermal patch and buccal film), Butorphanol, Codeine, Dihydrocodeine, Fentanyl, Hydrocodone, Hydromorphone, Levorphanol, Meperidine, Methadone, Morphine, Opium, Oxycodone, Oxymorphone, Pentazocine, Tapentadol, Tramadol</p>
Pharmacotherapy for Opioid Use Disorder (POD)	16 years and older	<p>The percentage of opioid use disorder (OUD) pharmacotherapy events that lasted at least 180 days among members 16 years of age and older with a diagnosis of OUD and a new OUD pharmacotherapy event.</p>	<p>Medication List Naltrexone (oral or injectable), Buprenorphine (sublingual tablet, injection, implant), Buprenorphine/naloxone (sublingual tablet, buccal film, sublingual film), Methadone (oral)</p>
Pharmacotherapy Management of COPD Exacerbation (PCE)	40 years and older	<p>The percentage of COPD exacerbations for members 40 years and older who had an acute inpatient discharge or ED visit on or between January 1 and November 30 of the measurement year and who were dispensed appropriate medications. Two rates are reported:</p> <ul style="list-style-type: none"> • Dispensed a Systemic Corticosteroid (or there was evidence of an active prescription) within 14 days of the event. • Dispensed a Bronchodilator (or there was evidence of an active prescription) within 30 days of the event. 	<p>Medication List Cortisone, Dexamethasone, Hydrocortisone, Methylprednisolone, Prednisolone, Prednisone Acidinium bromide, Ipratropium, Tiotropium, Umeclidinium Albuterol, Arformoterol, Formoterol, Indacaterol, Levalbuterol, Metaproterenol, Olodaterol, Salmeterol Albuterol-ipratropium, Budesonide-formoterol, Fluticasone-salmeterol, Fluticasone-vilanterol, Fluticasone furoate-umeclidinium-vilanterol, Formoterol-acidinium, Formoterol-glycopyrrolate, Formoterol-mometasone, Glycopyrrolate-indacaterol, Olodaterol- tiotropium, Umeclidinium-vilanterol</p>
Appropriate Treatment for Upper Respiratory Infection (URI)	3 months of age and older	<p>The percentage of episodes for members three months of age and older with a diagnosis of upper respiratory infection (URI) that did not result in an antibiotic dispensing event.</p>	<p>Medication List Amikacin, Gentamicin, Streptomycin, Tobramycin, Amoxicillin, Ampicillin, Amoxicillin-clavulanate, Ampicillin-sulbactam, Piperacillin-tazobactam, Cefadroxil, Cefazolin, Cephalexin, Cefepime, Clindamycin, Lincomycin, Azithromycin, Clarithromycin, Erythromycin, Aztreonam, Chlamydia oramphenicol, Dalofopristin-quinupristin, Daptomycin, Linezolid, Metronidazole, Vancomycin, Penicillin G benzathine-procaine, Penicillin G potassium, Penicillin G procaine, Penicillin G sodium, Penicillin V potassium, Penicillin G benzathine, Dicloxacillin, Nafcillin, Oxacillin, Ciprofloxacin, Gemifloxacin, Levofloxacin, Moxifloxacin, Ofloxacin, Rifampin, Cefaclor, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime, Sulfadiazine, Sulfamethoxazole-trimethoprim, Doxycycline, Minocycline, Tetracycline Cefdinir, Cefixime, Cefotaxime, Cefpodoxime, Ceftazidime, Ceftriaxone, Fosfomicin, Nitrofurantoin, Nitrofurantoin macrocrystals-monohydrate, Trimethoprim</p>
Antidepressant Medication Management (AMM)	18 years and older	<p>For members diagnosed with major depression and newly treated with antidepressant medication, two rates are reported:</p> <ul style="list-style-type: none"> • Effective Acute Phase Treatment: Members who remained on an antidepressant medication for at least 84 days (12 weeks). • Effective Continuation Phase Treatment: Members who remained on an antidepressant medication for at least 180 days (6 months). 	<p>Medication List: Bupropion, Vilazodone, Vortioxetine, Isocarboxazid, Phenelzine, Selegiline, Tranylcypromine, Nefazodone, Trazodone, Amitriptyline-chlordiazepoxide, Amitriptyline- perphenazine, Fluoxetine-olanzapine, Desvenlafaxine, Duloxetine, Levomilnacipran, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Maprotiline, Mirtazapine, Amitriptyline, Amoxapine, Clomipramine, Desipramine, Doxepin (>6 mg), Imipramine, Nortriptyline, Protriptyline, Trimipramine</p>



MY2025 MEDICAID HEDIS[®]

REFERENCE SHEET FOR PROVIDERS

Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA)	19-64 years	The percentage of members 18 years of age and older during the measurement year with schizophrenia or schizoaffective disorder who was dispensed and remained on an antipsychotic medication for at least 80% of their treatment period.	<p>Medication List: Aripiprazole, Asenapine, Brexpiprazole, Cariprazine, Clozapine, Haloperidol, Iloperidone, Loxapine, Lumateperone, Lurasidone, Molindone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone Chlorpromazine, Fluphenazine, Perphenazine, Prochlorperazine, Thioridazine, Trifluoperazine Amitriptyline-perphenazine Thiothixene</p>
Follow-up After Emergency Department Visit for Mental Illness (FUM)	6 years and old	<p>The percentage of emergency department (ED) visits for members 6 years of age and older with a principal diagnosis of mental illness or intentional self-harm, who had a follow-up visit for mental illness. Two rates are reported:</p> <ul style="list-style-type: none"> The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days). The percentage of ED visits for which the members received follow-up within 7 days of the ED visit (8 total days). 	<p>Codes to Identify Follow-up Visits: (visit with any practitioner and must include principal diagnosis) CPT with POS: 02, 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 22, 33, 49, 50, 71, 72: 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99510 HCPCS: G0155, G0176, G0177, G0409-G0411, G0463, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, S0201, S9480, S9484, S9485, T1015 CPT with POS: 03, 05, 07, 09, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 33, 49, 50, 52, 53, 57, 71, 72: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90867-90870, 90875, 90876 CPT with POS 52, 53: 99221-99223, 99231-99233, 99238, 99239, 99251-99255</p>
Follow-up After Emergency Department Visit for Substance Use (FUA)	13 years and older	<p>The percentage of emergency department (ED) visits for members 13 years of age and older with a principal diagnosis of substance use disorder (SUD), or any diagnosis of drug overdose, for which there was follow-up. Two rates are reported:</p> <ul style="list-style-type: none"> The percentage of ED visits for which the member received follow-up within 30 days of the ED visit (31 total days). The percentage of ED visits for which the member received follow-up within 7 days of the ED visit (8 total days). 	<p>Outpatient Visit with any diagnosis of SUD, substance use, or drug overdose or with a mental health provider CPT Visit Setting Unspecified: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875-90876, 99221-99223, 99231-99233, 99238-99239, 99252-99255 with Outpatient POS: 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71, 72</p>
Follow-up After Hospitalization for Mental Illness (FUH)	6 years and older	<p>The percentage of discharges for members six years of age and older who were hospitalized for a principal diagnosis of mental illness, or any diagnosis of intentional self-harm, and who had mental health follow-up service. Visits must occur after the date of discharge. Two rates are reported:</p> <ul style="list-style-type: none"> The percentage of discharges for which the member received follow-up within 30 days after discharge. The percentage of discharges for which the members received follow-up within 7 days after discharge. 	<p>Codes to Identify Visits (must be with mental health practitioner) CPT: 98960-98962, 99078, 99201-99205, 99211-99215, 99217-99220, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510 HCPCS: G0155, G0176, G0177, G0182 G0409-G0411, G0463, G0512, G9473-G9479, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, Q5003- Q5010, S0201, S9126, S9480, S9484, S9485, T1015, T2042-T2046 CPT with POS 03, 05, 07, 09, 11, 12, 13, 14, 15, 20, 22, 24, 33, 49, 50, 52, 53, 71, 72: 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90870, 90875, 90876 CPT with POS 52, 53: 99221-99223, 99231-99233, 99238, 99239, 99251-99255</p>
Initiation and Engagement of Substance Use Disorder Treatment (IET)	13 years and older	<p>The percentage of new substance use disorder (SUD) episodes that result in treatment initiation and engagement. Two rates are reported:</p> <ul style="list-style-type: none"> Initiation of SUD Treatment: The percentage of new SUD episodes that result in treatment initiation through an inpatient SUD admission, outpatient visit, intensive outpatient encounter, partial hospitalization, telehealth visits or medication treatment within 14 days. Engagement of SUD Treatment: The percentage of new SUD episodes that 	<p>Codes to Identify Follow up Visits (must include primary diagnosis of substance use disorder) CPT: 98960-98962, 99078, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99384-99387, 99391-99397, 99401-99404, 99411, 99412, 99483, 99492-99494, 99510 CPT with POS 02, 52, 53: 99221-99223, 99231-99233, 99238, 99239, 99251-99255</p>



MY2025 MEDICAID HEDIS® REFERENCE SHEET FOR PROVIDERS

		have evidence of treatment engagement within 34 days of initiation.	
Adult Immunization Status (AIS-E)	19 years and older	The percentage of members 19 years of age and older who are up to date on recommended routine vaccines for influenza, tetanus and diphtheria (Td), or tetanus, diphtheria and acellular pertussis (Tdap), zoster and pneumococcal and hepatitis B.	<p>Adult Influenza Vaccine Procedure CPT: 90630, 90653, 90654, 90656, 90658, 90661, 90662, 90673, 90674, 90682, 90686, 90688, 90689, 90694, 90756</p> <p>Adult Pneumococcal Vaccine Procedure CPT: 90670, 90671, 90677, 90732 HCPCS: G0009</p> <p>Hepatitis B Vaccine Procedure CPT: 90697, 90723, 90739, 90740, 90743, 90744, 90746, 90747, 90748, 90759 HCPCS: G0010</p> <p>Herpes Zoster Live Vaccine Procedure CPT: 90736</p> <p>Herpes Zoster Recombinant Vaccine Procedure CPT: 90750</p> <p>Influenza Virus LAIV Vaccine Procedure CPT: 90660, 90672</p> <p>Td Vaccine Procedure CPT: 90714</p> <p>Tdap Vaccine Procedure CPT: 90715</p>
Cervical Cancer Screening (CCS-E)	21-64 years	<p>The percentage of members 21-64 years of age who were recommended for routine cervical cancer screening and were screened for cervical cancer using any of the following criteria:</p> <ul style="list-style-type: none"> Members 21-64 years of age who were recommended for routine cervical cancer screening and had cervical cytology performed within the last 3 years. Members 30-64 years of age who were recommended for routine cervical cancer screening and had cervical high-risk human papillomavirus (hrHPV) testing performed within the last 5 years. Members 30-64 years of age who were recommended for routine cervical cancer screening and had cervical cytology/high-risk human papillomavirus (hrHPV) testing performed within the last 5 years. 	<p>Cervical Cytology Lab Test CPT: 88141-88143, 88147, 88148, 88150, 88152, 88153, 88164-88167, 88174, 88175 HCPCS: G0123, G0124, G0141, G0143-G0145, G0147-G0148, P3000, P3001, Q0091</p> <p>High-Risk HPV Test CPT: 87624, 87625 HCPCS: G0476</p>
Chlamydia Screening (CHL)	16-24 years	The percentage of members 16-24 years of age who were recommended for routine chlamydia screening, were identified as sexually active and had at least one test for chlamydia during the measurement year.	<p>Chlamydia Test CPT: 75580, 87110, 87270, 87320, 87490-87492, 87810</p>
Controlling High Blood Pressure (CBP)	18-85 (hypertensive members)	The percentage of members 18-85 years of age who had a diagnosis of hypertension (HTN) and whose blood pressure (BP) was adequately controlled (<140/90 mm Hg) during the measurement year.	<p>Codes to Identify Hypertension *ICD-10: I10 CPT: 99453, 99454, 99457 CPT II: 3074F, 3075F, 3077F, 3078F, 3079F, 3080F *with a DX of HTN prior to June 30th Telephone Visit: 98966-98968, 99441-99443</p>



MY2025 MEDICAID HEDIS® REFERENCE SHEET FOR PROVIDERS

<p>Depression Screening and Follow-Up for Adolescents and Adults (DSF-E)</p>	<p>12 years of age and older</p>	<p>The percentage of members 12 years of age and older who were screened for clinical depression using a standardized instrument and, if screened positive, received follow-up care.</p> <ul style="list-style-type: none"> • Depression Screening: The percentage of members who were screened for clinical depression using a standardized instrument. • Follow-Up on Positive Screen: The percentage of members who received follow-up care within 30 days of a positive depression screen finding. 	<p>Depression Case Management Encounter CPT: 99366, 99492-99494</p> <p>Behavioral Health Encounter CPT: 90791, 90792, 90832-90834, 90836-90839, 90845-90847, 90849, 90853, 90865, 90867-90870, 90875, 90876, 90880, 90887, 99484, 99492, 99493</p> <p>Follow Up Visit CPT: 98960-98962, 98966-98968, 98970-98972, 98980, 98981, 99078, 99202-99205, 99211-99215, 99242-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99421-99423, 99441-99443, 99457, 99458, 99483</p>
<p>Avoidance of Antibiotic Treatment for Acute Bronchitis/Bronchiolitis (AAB)</p>	<p>3 months & older</p>	<p>The percentage of episodes for members ages 3 months and older, continuously enrolled without a gap of coverage from 30 days prior to the episode date through 3 days after the episode date (34 total days), with a diagnosis of acute bronchitis or bronchiolitis that did not result in an antibiotic dispensing event.</p>	<p>Medications Aminoglycosides Amikacin, Gentamicin, Streptomycin, Tobramycin Aminopenicillins Amoxicillin, Ampicillin Beta-lactamase Inhibitors Amoxicillin-clavulanate, Ampicillin-sulbactam, Piperacillin-tazobactam First-generation Cephalosporins Cefadroxil, Cefazolin, Cephalexin Fourth generation Cephalosporins Cefepime Lincomycin Derivatives Clindamycin, Lincomycin Macrolides Azithromycin, Clarithromycin, Erythromycin Miscellaneous Antibiotics Aztreonam, Chloramphenicol, Dalpofristin-quinupristin, Daptomycin, Linezolid, Metronidazole, Vancomycin Natural Penicillin Penicillin G benzathine-procaine, Penicillin G potassium, Penicillin G procaine, Penicillin G sodium, Penicillin V potassium, Penicillin G benzathine Penicillinase Resistant Penicillin Dicloxacillin, Nafcillin, Oxacillin Quinolones Ciprofloxacin, Gemifloxacin, Levofloxacin, Moxifloxacin, Ofloxacin Rifamycin Derivatives Rifampin Second-generation Cephalosporin Cefaclor, Cefotetan, Cefoxitin, Cefprozil, Cefuroxime Sulfonamides Sulfadiazine, Sulfamethoxazole-trimethoprim Tetracyclines Doxycycline, Minocycline, Tetracycline Third generation Cephalosporins Cefdinir, Cefixime, Cefotaxime, Cefpodoxime, Ceftazidime, Ceftriaxone Urinary Anti-infectives Fosfomycin, Nitrofurantoin, Nitrofurantoin macrocrystals-monohydrate, Trimethoprim</p>
<p>Asthma Medication Ratio (AMR)</p>	<p>5-64 years</p>	<p>The percentage of members 5-64 years of age who were identified as having persistent asthma and had a ratio of controller medications to total asthma medications of 0.50 or greater during the measurement year.</p>	<p>Medication List Antibody Inhibitors Omalizumab Anti-interleukin-4 Dupilumab Anti-interleukin 5 Benralizumab, Mepolizumab, Reslizumab , Budesonide-formoterol, Fluticasone-salmeterol, Fluticasone-vilanterol, Formoterol/mometasone Inhaled Corticosteroids Beclomethasone, Budesonide, Ciclesonide, Flunisolide, Fluticasone, Mometasone Leukotriene Modifiers Montelukast, Zafirlukast, Zileuton Methylxanthines Theophylline</p>
<p>Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM-E)</p>	<p>1-17 years</p>	<p>The percentage of children or adolescents 1-17 years of age who had two or more antipsychotic prescriptions and had metabolic testing. Three rates are reported:</p>	<p>Glucose Lab Test CPT: 80047, 80048, 80050, 80053, 80069, 82947, 82950, 82951 HbA1c Lab Test CPT: 83036, 83037 Cholesterol Lab Test CPT: 82465, 83718, 83722, 84478 LDL C Tab Test CPT: 80061, 83700, 83701, 83704, 83721</p>
<p>Breast Cancer Screening (BCS-E)</p>	<p>50-74 years</p>	<p>The percentage of members 50–74 years of age who were recommended for a routine breast cancer screening and had a mammogram to screen for breast cancer between October 1 two years prior to the measurement year through December 31 of the measurement year (e.g., between 10/1/23 and 12/31/25 [MY 25]).</p>	<p>Mammography CPT: 77061-77063, 77065-77067</p>



MY2025 MEDICAID HEDIS[®] REFERENCE SHEET FOR PROVIDERS

Prenatal Depression Screening and Follow-Up (PND-E)	Pregnant Women	The percentage of deliveries in which members were screened for clinical depression while pregnant and, if screened positive, received follow-up care.	Behavioral Health Encounter CPT: 90791, 90792, 90832-90834, 90836-90839, 90845-90847, 90849, 90853, 90865, 90867-90870, 90875, 90876, 90880, 90887, 99484, 99492, 99493 Depression Case Management Encounter CPT: 99366, 99492-99494 Follow-Up Visit CPT: 98960-98962, 98966-98968, 98970-98972, 98980, 98981, 99078, 99202- 99205, 99211-99215, 99242-99245, 99341, 99342, 99344, 99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99421-99423, 99441- 99443, 99457, 99458, 99483
Postpartum Depression Screening and Follow-Up (PDS-E)	Pregnant Women	The percentage of deliveries in which members were screened for clinical depression during the postpartum period, and if screened positive, received follow-up care. The participation period is the delivery date through 60 days following the date of delivery.	Behavioral Health Encounter CPT: 90791, 90792, 90832-90834, 90836-90839, 90845-90847, 90849, 90853, 90865, 90867-90870, 90875, 90876, 90880, 90887, 99484, 99492, 99493 Depression Case Management Encounter CPT: 99366, 99492-99494 Follow-Up Visit CPT: 98960-98962, 98966-98968, 98970-98972, 98980, 98981, 99078, 99202- 99205, 99211-99215, 99242-99245, 99341, 99342, 99344, 99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411, 99412, 99421-99423, 99441- 99443, 99457, 99458, 99483
Prenatal Immunization Status (PRS-E)	Pregnant Women	The percentage of deliveries in the measurement period (January 1 - December 31) in which members had received influenza and tetanus, diphtheria toxoids and acellular pertussis (Tdap) vaccinations.	Adult Influenza Vaccine Procedure CPT: 90630, 90653, 90654, 90656, 90658, 90661, 90662, 90673, 90674, 90682, 90686, 90688, 90689, 90694, 90756 Tdap Vaccine Procedure CPT: 90715